CCL2/CCR2 signaling-mediated microglial migration leads to cerebral small vessel dysfunction in chronic hypertension

Takashi Koizumi1, Eline M Herckenrath1, Katsutoshi Taguchi1

  • 1Department of Anatomy and Neurobiology, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kamigyo-ku, Kyoto 602-8566, Japan.

Experimental Neurology
|February 25, 2025
PubMed

Insights

In chronic hypertension, CC motif chemokine ligand 2 (CCL2)/CC chemokine receptor type 2 (CCR2) signaling drives vessel-associated microglia (VAM) accumulation. Inhibiting this pathway may prevent hypertensive cerebral small vessel disease.

Area of Science:

  • Neuroscience
  • Immunology
  • Cardiovascular Research

Background:

  • Microglia are key brain immune cells regulating homeostasis.
  • Vessel-associated microglia (VAM) are implicated in blood-brain barrier integrity during disease.
  • Hypertension is a primary driver of cerebral small vessel disease (CSVD).

Purpose of the Study:

  • To investigate the role of VAM in chronic hypertension-induced CSVD.
  • To elucidate the signaling pathways involved in VAM accumulation during hypertension.

Main Methods:

  • Utilized a deoxycorticosterone-acetate-salt induced chronic hypertensive rat model.
  • Investigated the involvement of CC motif chemokine ligand 2 (CCL2)/CC chemokine receptor type 2 (CCR2) signaling.
  • Assessed VAM numbers and astrocytic endfeet integrity.

Main Results:

  • CCL2/CCR2 signaling was crucial for increased VAM in early hypertension.
  • This signaling promoted microglial migration toward cerebral vessels.
  • Inhibition of CCL2/CCR2 signaling reduced VAM and preserved astrocytic endfeet in late hypertension.

Conclusions:

  • CCL2/CCR2 signaling acts as a trigger for microglial migration in hypertensive CSVD.
  • Targeting CCL2/CCR2 signaling offers a potential therapeutic strategy for preventing hypertensive CSVD.

Related Concept Videos